What evidence supports using continuous androgen‑deprivation therapy with abiraterone acetate as first‑line treatment for men with high‑volume metastatic castration‑sensitive prostate cancer?

ADT Plus Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer

For men with high-volume metastatic castration-sensitive prostate cancer, adding abiraterone acetate 1000 mg daily plus prednisone 5 mg daily to continuous androgen deprivation therapy is strongly recommended and should be offered as standard first-line treatment. 1

Evidence Quality and Strength

The recommendation is based on two landmark randomized controlled trials that demonstrated substantial survival benefits:

• LATITUDE trial enrolled 1,199 men with newly diagnosed high-risk metastatic castration-sensitive disease (defined as ≥2 of: Gleason ≥8, ≥3 bone lesions, or visceral metastases) and showed median overall survival of 53.3 months with abiraterone versus 36.5 months with placebo (HR 0.66,95% CI 0.56-0.78; P<0.0001). 2, 3

• STAMPEDE trial demonstrated similar survival benefits across a broader population including both high-risk and lower-risk metastatic disease, supporting use beyond just the LATITUDE high-risk definition. 1

The evidence quality is rated as strong by ASCO, with a strong recommendation for this combination therapy. 1

Treatment Algorithm for High-Volume Disease

Step 1: Define High-Volume Disease

High-volume disease is specifically defined as ≥4 bone metastases with ≥1 outside the spine/pelvis, OR any visceral metastases (CHAARTED criteria). 1 This definition is agnostic to nodal disease presence. 1

Step 2: Initiate Treatment Regimen

• Abiraterone acetate: 1000 mg orally once daily on an empty stomach (≥1 hour before or ≥2 hours after meals) 4, 5
• Prednisone: 5 mg orally once daily 1, 4
• Continuous ADT: LHRH agonist, LHRH antagonist, or bilateral orchiectomy, continued indefinitely 1, 4
• Duration: Continue abiraterone until progression to castration-resistant disease 4, 5

Step 3: Mandatory Baseline Assessment

Before initiating abiraterone, obtain: 4, 5

• Blood pressure measurement
• Serum potassium and liver function tests
• Cardiac evaluation (especially in patients with cardiovascular history)

Expected Adverse Events and Management

Mineralocorticoid-Related Effects (Most Common)

• Hypertension: 21% grade 3-4 4, 2
• Hypokalemia: 12% grade 3-4 4, 2
• Peripheral edema: 28% any grade 4

Other Significant Toxicities

• Hepatotoxicity: 7% grade 3-5 liver enzyme elevations 4, 5
• Cardiac disorders: 10% severe hypertension or cardiac events 5

Monitoring Schedule

• Monthly (at minimum): blood pressure, serum potassium, liver function tests 4, 5
• Correct hypokalemia promptly before it becomes severe 5

Critical Pitfalls to Avoid

Do NOT use spironolactone for mineralocorticoid-related side effects, as it interferes with abiraterone's mechanism of action. 4, 5

Do NOT combine abiraterone with radium-223, as this increases fracture risk without improving symptomatic skeletal event-free survival. 4, 5

Do NOT administer abiraterone with food, as this significantly increases drug exposure and unpredictable absorption. 4, 5

Do NOT discontinue ADT when adding abiraterone; continuous androgen deprivation must be maintained indefinitely regardless of additional therapies. 1

Quality of Life Benefits

Beyond survival, abiraterone addition provides measurable quality-of-life improvements: 6

• Pain progression: Median time to worst pain not reached versus 5.6 months with ADT alone (HR 0.63, P<0.0001) 6
• Fatigue progression: Median time to worst fatigue not reached versus 6.5 months (HR 0.65, P=0.0001) 6
• Functional status: Median time to deterioration 12.9 months versus 8.3 months (HR 0.85, P=0.032) 6

Comparison with Docetaxel

While docetaxel plus ADT is an alternative for high-volume disease, the strongest evidence for docetaxel is specifically in de novo metastatic high-volume disease. 1 The CHAARTED subset analysis did not demonstrate survival benefit for low-volume disease, and GETUG-15 was negative. 1

There are no head-to-head trials comparing abiraterone versus docetaxel in this setting. 1 The choice between them should consider: 1

• Patient fitness for chemotherapy
• Comorbidities (particularly cardiovascular for abiraterone, neuropathy risk for docetaxel)
• Patient preference regarding toxicity profiles
• Drug availability and cost

Combining or sequencing both abiraterone and docetaxel upfront is NOT recommended due to insufficient evidence. 1

Age-Related Considerations

Patients ≥70 years experience higher rates of grade 3-5 adverse events (47% versus 33%) with abiraterone and may have attenuated survival benefits (HR 0.94 in older men versus HR 0.51 in men <70 years). 5 Exercise increased caution and closer monitoring in elderly patients, particularly those with cardiovascular comorbidities. 5